Anzeige
Meldung des Tages: Unter dem Radar, voll finanziert: Beginnt jetzt der nächste Gold-Run?

Compugen News

Aktie
WKN:  553001 ISIN:  IL0010852080 US-Symbol:  CGEN Branche:  Biotechnologie Land:  Israel
2,885 $
+0,135 $
+4,91%
2,4456 € 19:03:03 Uhr
Depot/Watchlist
Marktkapitalisierung *
122,33 Mio. €
Streubesitz
84,32%
KGV
-
Index-Zuordnung
-

Compugen News

09.04.26 - PR Newswire
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference PR Newswire
02.03.26 - PR Newswire
Compugen Reports Fourth Quarter and Full Year 2025 Results
Compugen Reports Fourth Quarter and Full Year 2025 Results PR Newswire
19.02.26 - PR Newswire
Compugen to Participate in Upcoming Investor Conferences
Compugen to Participate in Upcoming Investor Conferences PR Newswire
17.02.26 - PR Newswire
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 PR Newswire
12.02.26 - PR Newswire
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors PR Newswire
17.12.25 - PR Newswire
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million PR Newswire
10.11.25 - PR Newswire
Compugen Reports Third Quarter 2025 Results
Compugen Reports Third Quarter 2025 Results PR Newswire
04.11.25 - PR Newswire
Compugen to Participate in Stifel 2025 Healthcare Conference
Compugen to Participate in Stifel 2025 Healthcare Conference PR Newswire
27.10.25 - PR Newswire
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 PR Newswire
13.10.25 - PR Newswire
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 PR Newswire
06.10.25 - PR Newswire
Compugen to Present at SITC 2025
Compugen to Present at SITC 2025 PR Newswire
08.09.25 - PR Newswire
Compugen to Present Research at the Single Cell Genomics 2025 Conference
Compugen to Present Research at the Single Cell Genomics 2025 Conference PR Newswire
28.08.25 - PR Newswire
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
06.08.25 - PR Newswire
Compugen Reports Second Quarter 2025 Results
Compugen Reports Second Quarter 2025 Results PR Newswire
28.07.25 - PR Newswire
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 PR Newswire
23.07.25 - PR Newswire
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 PR Newswire
21.07.25 - PR Newswire
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer PR Newswire
12.06.25 - PR Newswire
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences PR Newswire
19.05.25 - PR Newswire
Compugen Reports First Quarter 2025 Results
Compugen Reports First Quarter 2025 Results PR Newswire
13.05.25 - PR Newswire
Compugen Announces Leadership Transitions Effective September 2025
Compugen Announces Leadership Transitions Effective September 2025 PR Newswire

Newssuche

Videos

newspaper
07.04.26 +4,20%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »